Singapore based biotechnology company and leader in cord lining stem cells, CellResearch Corporation has appointed Abbas Hussain and Richard Davies as Senior Advisors to CellResearch’s Board, effective immediately.
CellResearch identified the broad applicability of cord lining mesenchymal and epithelial stem cells as potential treatments for an extensive number of indications including Haemophilia A, myocardial infarction and Parkinson’s disease.
Gavin Tan, CEO of CellResearch Corporation, said: “Abbas and Richard bring a wealth of global, senior experience in the healthcare industry and I am delighted to have welcomed them to our growing team. Their appointments represent an important step for CellResearch as we continue to build our capabilities in development and commercial excellence.”
Abbas Hussain has served the advisory board of CellResearch Corporation since August 2017, following a successful career in pharmaceutical leadership.
Abbas Hussain commented: “I have known the CellResearch team for some time and am pleased to have become a senior advisor to the board. The company is led by an ambitious team and I look forward to continuing my work with them as they move into an important phase of development and look to realise their near-term commercialisation opportunities.”
Abbas Hussain is Senior Advisor at C-Bridge Capital as well as non-executive Director of Immunocore, Vigor Medical Systems and CSL.
He was previously Global President, Pharmaceuticals and Vaccines at GlaxoSmithKline where, under his leadership, GSK delivered a series of successful new product launches, implemented a flexible approach to pricing across developing countries, and implemented a new commercial operating model across more than 100 countries.
Focusing on the company’s wholly-owned cellular therapeutics subsidiary, Richard Davies will offer his guidance and expertise on the commercialisation of CorLiCyte, an umbilical cord lining stem cell cellular therapeutic, in his role as Senior Advisor.
The unique platform is based on cord lining mesenchymal stem cells and is currently being developed for the topical treatment of chronic wounds and ulcers reducing the need for skin grafts. The company has established robust IP protection for CorLiCyte and reported positive results from a number of studies.
“I am delighted to join the pioneering team behind CorLiCyte at a pivotal time for the organisation. I look forward to advising and guiding the team on realising the broad potential that the CorLiCyte cellular therapeutic platform has, to transform the way some of the world’s most prevalent diseases are treated,” commented Richard Davies.
Davies brings more than 27 years of experience in the global healthcare industry in roles that spanned business development, commercialisation and sales. Davies is currently chairman of the board at Alvotech, a pioneering biosimilars company and has previously served on the boards of Zydus Hospira Oncology and Medicines Australia.
